Integra LifeSciences and Johnson and Johnson (J&J) have decided to divest five neurosurgical medical device product lines to Natus Medical to settle a complaint filed by the Federal Trade Commission (FTC).
The complaint was filed against Integra’s proposed $1bn acquisition of J&J’s Codman Neuro division and stated that the deal would have a negative impact on neurological devices market in the US.
As per the Commission, the impacted device markets would include intracranial pressure monitoring, cerebrospinal fluid collection and fixed-pressure valve shunt systems, non-antimicrobial external ventricular drainage catheters, and dural grafts.
In the country, Integra and Codman account for 94% of the intracranial pressure monitoring systems market, 71% of the cerebrospinal fluid collection systems, 46% of the non-antimicrobial external ventricular drainage catheters, 38% for fixed pressure valve shunt systems, and 75% for dural grafts.
A consent agreement signed by Integra and J&J allows the Commission to monitor compliance with the orders on divestment.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
Integra and J&J entered a binding offer in February for the Codman Neurosurgery business, which includes hydrocephalus, neuro-critical care, and operative neurosurgery devices.
The devices are expected to complement Integra’s portfolio of tissue ablation, dural repair, and cranial stabilisation products, allowing it to offer the entire range of neurosurgical solutions.